Screener / SEC EDGAR /CIK 0001393434 /10-K filed Feb 5, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ocular Therapeutix, Inc OCUL

Compare with peers Embed
SEC comment letters, last 20 years

1 review of OCUL's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter May 23, 2014
Questions asked 31 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 31 numbered comments
  3. 3. Company replies 0 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2014-05-23 to 2014-06-18 · 31 questions · 2 letters from the SEC, 0 from the company
No closing letter
Risk factorsLiquidity and cashDebtRevenueCritical estimatesInventory
SEC letter of May 23, 2014 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
We note that you have submitted an application for confidential treatment relating to certain of your exhibits. Please be advised that comments to this application, if any, will be sent under separate cover and that any such comments must be resolved prior to your requesting effectiveness of your registration statement.
OCUL answered

No reply letter found.

General
SEC asked (2)
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
OCUL answered

No reply letter found.

General
SEC asked (3)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
Rest of the question

Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.

OCUL answered

No reply letter found.

Summary · Overview of Ocular Therapeutics, page 1
SEC asked (4)
Please define the terms “hydrogel” and “intravitreal” in this section.
OCUL answered

No reply letter found.

Summary · Overview of Ocular Therapeutics, page 1
SEC asked (5)
Please note here that your entire intellectual property portfolio and much of the technology you utilize is licensed from Incept, LLC, a related party.
OCUL answered

No reply letter found.

Anticipated Benefits of our Punctum Plug Technology, page 3
SEC asked (6)
Please state the approximate amount of time it takes for your punctum plugs to dissipate after their active pharmaceutical ingredients have been exhausted.
OCUL answered

No reply letter found.

Overview of Our Key Product Candidates and Marketed Product, page 4
SEC asked (7)
Please briefly discuss the therapeutic effects of both dexamethasone and travoprost.
OCUL answered

No reply letter found.

Overview of Our Key Product Candidates and Marketed Product, page 4
SEC asked (8)
In your summary discussion of ReSure Sealant please disclose that you had previously initiated and then discontinued commercialization of an earlier version of this product in Europe and that the FDA also requested withdrawal of your initial application for that version.
OCUL answered

No reply letter found.

Risks Associated with Our Business, page 6
SEC asked (9)
Please include a bullet point summarizing the material risk discussed in the risk factor on pages 37-38 and cite the FDA’s condition requiring post-approval studies for ReSure Sealant as an example. Risk Factors Risks Related to Our Financial Position and Need for Additional Capital “Our substantial indebtedness may limit cash flow available to invest in the ongoing needs of our business,” page 15
OCUL answered

No reply letter found.

Risks Associated with Our Business, page 6
SEC asked (10)
Please provide examples of the types of corporate actions the restrictive covenants included in your credit agreement may prevent you from undertaking. Risks Related to Our Product Development “If clinical trials of our punctum plug product candidates or any other product candidate that we develop . . .,” page 17
OCUL answered

No reply letter found.

Risks Associated with Our Business, page 6
SEC asked (11)
Here, and wherever else applicable in your registration statement, please state the reason(s) to your knowledge that the FDA requested you withdraw your application for ReSure Sealant submitted under Section 510(k) of the FDCA. “If serious adverse or unacceptable side effects are identified during the development of our punctum plug product candidates . . .,” page 20
OCUL answered

No reply letter found.

Risks Associated with Our Business, page 6
SEC asked (12)
Please amend this risk factor to provide examples of the adverse events that have been identified in your clinical trials. Risks Related to Manufacturing “If our sole clinical manufacturing facility is damaged or destroyed or production at this facility is otherwise interrupted . . .,” page 22
OCUL answered

No reply letter found.

Risks Associated with Our Business, page 6
SEC asked (13)
Please amend this risk factor to include the limit of your insurance coverage.
OCUL answered

No reply letter found.

Risks Related to Commercialization · “Even though ReSure Sealant has received marketing approval from the FDA . . .,” page 23
SEC asked (14)
Here, on page 60 of your disclosure, and wherever else applicable in your registration statement, please cite the total revenue generated by ReSale Sealant during the period of commercialization in Europe.
OCUL answered

No reply letter found.

Special Note Regarding Forward-Looking Statements and Industry Data, page 48
SEC asked (15)
Please remove the last sentence of this section. Asserting that you have not independently verified information included in your registration statement can be construed as disclaiming responsibility for such information, which is not appropriate.
OCUL answered

No reply letter found.

Use of Proceeds, page 50
SEC asked (16)
Please include separate bullet points identifying the amount of net proceeds you intend to allocate toward expanding your manufacturing capacity and the amount to be allocated on sales and marketing activities, and remove the references to them from your last bullet point.
OCUL answered

No reply letter found.

Use of Proceeds, page 50
SEC asked (17)
Similarly, please include a separate bullet point that identifies the amount of net proceeds you intend to allocate toward preclinical product development and remove the reference to this from your last bullet point.
OCUL answered

No reply letter found.

Use of Proceeds, page 50
SEC asked (18)
Please include a separate bullet point that discloses the amount of net proceeds, if any, you intend to allocate toward payment of the loans you have borrowed under your credit facility.
OCUL answered

No reply letter found.

Critical Accounting Policies and Estimate · Determination of the Fair Value of Common Stock, page 67
SEC asked (19)
Please tell us the factors contributing to the increase in the common stock fair value of $0.94 on September 12, 2013 to $1.45 on November 7, 2013 to $3.33 on February 12, 2014. In addition, to the extent your estimated IPO price is significantly different from your most recent valuation at March 27, 2014, please tell us the factors contributing to the change in the common stock fair value.
Rest of the question

Please note that we will defer our evaluation of any stock compensation issues until an estimated IPO price has been determined.

OCUL answered

No reply letter found.

Options and Restricted Stock Granted, page 69
SEC asked (20)
Please provide us a table and narratives that disclose all equity issuances to date or confirm that no additional equity issuances such as options, warrants, preferred stock, common stock, etc. were made subsequent to April 14, 2014.
OCUL answered

No reply letter found.

Business
SEC asked (21)
In your discussion of clinical trials, please explain more clearly what the p-values and nvalues cited represent, where applicable.
OCUL answered

No reply letter found.

Dexamethasone Punctum Plug (OTX-DP), page 92
SEC asked (22)
Where you reference the three severe adverse events experienced by participants in the Phase 2 trial on page 97, please provide the basis for your assertion that they were unrelated to the study treatment.
OCUL answered

No reply letter found.

Travoprost Punctum Plug (OTX-TP), page 99
SEC asked (23)
In your discussion of the pilot studies and clinical study please state the reason(s) to your knowledge why certain of the plugs would not be retained over the entire study period.
OCUL answered

No reply letter found.

Moxifloxacin Punctum Plug (OTX-MP), page 105
SEC asked (24)
In your description of the clinical trial, please further explain your statement that 0% of the plugs being present at the end of the trial indicated that it functioned as designed.
OCUL answered

No reply letter found.

ReSure Sealant, page 106
SEC asked (25)
In your discussion of the pivotal clinical trial, please specify which p-value represents statistical significance.
OCUL answered

No reply letter found.

Government Regulation · General, page 116
SEC asked (26)
Please indicate the number of Investigational New Drug Application(s) you have filed with the FDA to date, the product candidate(s) and indication(s) to which they relate and the approximate date(s) when filed.
OCUL answered

No reply letter found.

Shares eligible for future sale · Lock-up Agreements, page 161
SEC asked (27)
Please file a copy of the form lock-up agreement as an exhibit to your registration statement or, alternatively, please confirm that it will be filed as an exhibit to your underwriting agreement. Financial Statements Notes to Financial Statements 2. Summary of Significant Accounting Policies
OCUL answered

No reply letter found.

Unaudited Pro Forma Information, page F-8
SEC asked (28)
Please tell us why you did not reflect the April 2014 financing in the pro forma here as you have in other parts of the filing.
OCUL answered

No reply letter found.

Inventory Valuation, page F-10
SEC asked (29)
Please disclose how much inventories were expensed during the periods presented in preparation for the launch of ReSure Sealant during the first quarter of 2014. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website at
Rest of the question

http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

OCUL answered

No reply letter found.

SEC letter of Jun 18, 2014 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
SEC asked (1)
We note your response to prior comment 11. Please explain why, to your knowledge, the FDA did not believe the technical characteristics of your earlier version of ReSure Sealant were substantially equivalent to a predicate device and also explain the significance of this determination.
OCUL answered

No reply letter found.

Business · Dexamethasone Punctum Plug (OTX-DP), page 97
SEC asked (2)
We note your response to prior comment 22. Please describe the factors that led your trial investigator to conclude that none of the serious adverse events identified were related to the study treatment. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11,
Rest of the question

2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm.

OCUL answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
14 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 16 letters filed since 2014-05-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OCUL/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.